San Diego-dependent Viking Therapeutics marked by itself as a significant competitor during the weight loss drug current market in February just after revealing promising data from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March